Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (2465)	4/25/2005 9:43:24 PM
From: zeta1961	Respond to of 12215

I'm beginning to think it's a double entendre..putting out the word to Wall St that they do have a 'suitor' My gut tells me it's bullish..things are brewing over there..other studies maturing, word about Advexin from FDA awaiting..Nance, the CEO, gets made fun of and caricatured by some because of his CC persona..but my experience of him via emails is of a businessman who is focused and remains with eye on goal..and has so not appreciated the trashing by Wall St and even lower tier analysts..you should have seen the recent R&R downgrade report..harsh, petty, deceptive.. edit: not implying R&R is lower tier..the albanian grammar getting in the way... From time to time, the YMB folk comment on him.. G. Thomas Finnegan Vice President, Finance and Corporate Development G. Thomas Finnegan III joined Introgen in March 2001 as Vice President of Finance and Corporate Development. From 1999 to March 2001, he was employed in the Health Care Investment Banking division of SG Cowen. From 1996 to 1997, he was an equity analyst for Forstmann Partners LP. Prior to 1996, he worked with various hedge funds as a trader and an analyst. Mr. Finnegan earned his M.B.A. from the Goizueta School of Business at Emory University and his B.A. in finance from the University of South Carolina. Still bizarre..! Thanks Tom..will keep you apprised<g> Zeta